A Study of LY2875358 in Japanese Participants With Advanced Cancer

NCT01602289 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Lymphoma
Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL: LY2875358
DRUG: Erlotinib
DRUG: Gefitinib

Sponsor

Eli Lilly and Company